Gabriela Restovic

Learn More
In Spain, various treatments are available to prevent osteoporotic fractures. A discrete choice experiment (DCE) was used to investigate the importance of different treatment aspects and its influence on patients’ preferences. All attributes included as type and place of drug administration as well as costs showed to be significant predictors of choice.(More)
PURPOSE To estimate the cost per skeletal-related event (SRE) in patients with bone metastases secondary to solid tumours in the Spanish healthcare setting. METHODS Patients diagnosed with bone metastases secondary to breast, prostate or lung cancer were included in this multicentre, observational study. SREs are defined as pathologic fracture (vertebral(More)
The aim of this study was to determine health care resource utilization and direct medical costs in Spanish patients treated with intravenous immunoglobulins (IVIGs) in 2009. Cost-of-illness analyses were performed to estimate direct medical costs of patients treated with IVIGs. Prevalence data were obtained from the Spanish Primary Immunodeficiency(More)
Objectives: This study aimed to adapt the ADPKD Outcomes Model in order to compare the Chronic Kidney Disease progression and relative costs of Autosomal Dominant Polycystic Kidney Disease (ADPKD)-affected patients treated with JINARC as compared to non-treated patients in Italy. MethOds: Utilising the structure of the ADPKD Outcomes Model adapted to the(More)
BACKGROUND In Spain, the decision of Price and Reimbursement (P&R) of a new drug must be taken between 180-270 days. The objective of this study was to assess the reimbursement timing in Spain for innovative drugs approved by the European Medicines Agency (EMA) between January 2008 and December 2013 and to explore the potential impact of drug's price on(More)
  • 1